{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:16Z","timestamp":1756902136431,"version":"3.44.0"},"reference-count":21,"publisher":"The Pediatric Pharmacy Association","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Limited data exist comparing indomethacin and ibuprofen for the treatment of patent ductus arteriosus (PDA). The objective was to compare the safety and efficacy of indomethacin and ibuprofen for treatment of PDA closure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This single-center, pre-test\/post-test quasi-experiment included preterm infants admitted to the neonatal intensive care unit who received indomethacin (July 1, 2013\u2013September 30, 2015) or ibuprofen (December 1, 2015\u2013July 31, 2019) for PDA. Patients were excluded if they were thrombocytopenic, had existing kidney injury, unresolved intraventricular hemorrhage (IVH) or necrotizing enterocolitis (NEC) at treatment initiation. Data were obtained from the electronic health record. Study outcomes were complete PDA closure, degree of PDA closure, resolution of symptoms, and new-onset acute kidney injury (AKI), IVH, or NEC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 114 patients were included: 44 (39%) received indomethacin and 70 (61%) received \u00adibuprofen. Twenty-one (21%) patients experienced successful PDA closure within 1 week: 13 (32%) indomethacin patients and 8 (13%) ibuprofen patients (p = 0.023). PDA size reduction occurred in 43 (46%) patients with 29 (25%) experiencing complete symptom resolution. Significantly more indomethacin patients compared with ibuprofen patients experienced new-onset AKI (48% vs 17%; p &amp;lt; 0.001) and received concomitant nephrotoxins (68% vs 39%; p = 0.002). There were no significant differences in new-onset IVH or NEC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Indomethacin administration successfully closed the PDA in more neonates than ibuprofen but resulted in higher rates of AKI. However, this was confounded by more frequent administration of concomitant nephrotoxins. Larger trials are needed to help elucidate the optimal drug for closure of the PDA in neonates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-28.7.618","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T08:58:42Z","timestamp":1701161922000},"page":"618-627","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Closure of Patent Ductus Arteriosus With Ibuprofen Compared to Indomethacin"],"prefix":"10.5863","volume":"28","author":[{"given":"Cory D.","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Pharmacy (CJ), Jefferson Regional Medical Center, Pine Bluff, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda C.","family":"Capino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (AC), University of Mississippi School of Pharmacy, Jackson, MS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay H.","family":"Stuart","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pharmacy (LS), University of Mississippi Medical Center, Jackson, MS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (JW), University of Mississippi School of Pharmacy, Jackson, MS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2023112808583333000_i2331-348X-28-7-618-b1","doi-asserted-by":"crossref","first-page":"1438038","DOI":"10.1155\/2017\/1438038","article-title":"Paracetamol in patent ductus arteriosus treatment: efficacious and safe?","volume":"2017","author":"Bardanzellu","year":"2017","journal-title":"BioMed Res Int"},{"first-page":"2","year":"2017","author":"Lunberry","key":"2023112808583333000_i2331-348X-28-7-618-b2"},{"issue":"(1)","key":"2023112808583333000_i2331-348X-28-7-618-b3","doi-asserted-by":"crossref","first-page":"e20153730","DOI":"10.1542\/peds.2015-3730","article-title":"Patent ductus arteriosus in preterm infants","volume":"137","author":"Benitz","year":"2016","journal-title":"Pediatrics"},{"issue":"(6)","key":"2023112808583333000_i2331-348X-28-7-618-b4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jpeds.2007.05.007","article-title":"Risk factors for persistent ductus arteriosus patency during indomethacin treatment","volume":"151","author":"Chorne","year":"2007","journal-title":"J Pediatr"},{"issue":"(2)","key":"2023112808583333000_i2331-348X-28-7-618-b5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pedneo.2019.10.002","article-title":"Therapeutic strategy of patent ductus arteriosus in extremely preterm infants","volume":"61","author":"Su","year":"2020","journal-title":"Pediatr Neonatol"},{"issue":"(12)","key":"2023112808583333000_i2331-348X-28-7-618-b6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jama.2018.1896","article-title":"Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis","volume":"319","author":"Mitra","year":"2018","journal-title":"JAMA"},{"key":"2023112808583333000_i2331-348X-28-7-618-b7","first-page":"CD003481","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm and\/or low birth weight infants","volume":"4","author":"Ohlsson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"(4)","key":"2023112808583333000_i2331-348X-28-7-618-b8","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/PCC.0b013e3182745675","article-title":"Pediatric risk, injury, failure, loss, end-stage renal disease score identifies acute kidney injury and predicts mortality in critically ill children: a prospective study","volume":"14","author":"Soler","year":"2013","journal-title":"Pediatr Crit Care Med"},{"issue":"(3)","key":"2023112808583333000_i2331-348X-28-7-618-b9","first-page":"205","article-title":"Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications","volume":"20","author":"Chan","year":"2014","journal-title":"Hong Kong Med J"},{"issue":"(3)","key":"2023112808583333000_i2331-348X-28-7-618-b10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jpeds.2006.12.048","article-title":"Patient ductus arteriosus: evidence for and against treatment","volume":"150","author":"Clyman","year":"2007","journal-title":"J Pediatr"},{"issue":"(5)","key":"2023112808583333000_i2331-348X-28-7-618-b11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0022-3476(96)80123-5","article-title":"Recommendations for the postnatal use of indomethacin: an analysis of four treatment strategies","volume":"128","author":"Clyman","year":"1996","journal-title":"J Pediatr"},{"issue":"(5)","key":"2023112808583333000_i2331-348X-28-7-618-b12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1542\/peds.62.5.706","article-title":"Age-dependent closure of the patent ductus arteriosus by indomethacin","volume":"62","author":"McCarthy","year":"1978","journal-title":"Pediatrics"},{"issue":"(4)","key":"2023112808583333000_i2331-348X-28-7-618-b13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1542\/peds.2005-1528","article-title":"Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less","volume":"117","author":"Koch","year":"2006","journal-title":"Pediatrics"},{"key":"2023112808583333000_i2331-348X-28-7-618-b14","first-page":"CD003481","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants","volume":"2","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"(6)","key":"2023112808583333000_i2331-348X-28-7-618-b15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/archdischild-2013-303688","article-title":"Paracetamol to induce ductus arteriosus closure: is it valid?","volume":"98","author":"Allegaert","year":"2013","journal-title":"Arch Dis Child"},{"issue":"(1)","key":"2023112808583333000_i2331-348X-28-7-618-b16","first-page":"CD010061","article-title":"Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants","volume":"4","author":"Ohlsson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"(2)","key":"2023112808583333000_i2331-348X-28-7-618-b17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00431-016-2830-7","article-title":"Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates","volume":"176","author":"El-Mashad","year":"2017","journal-title":"Eur J Pediatr"},{"key":"2023112808583333000_i2331-348X-28-7-618-b18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jpeds.2018.09.012","article-title":"PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age","volume":"205","author":"Clyman","year":"2019","journal-title":"J Pediatr"},{"issue":"(5)","key":"2023112808583333000_i2331-348X-28-7-618-b19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41372-019-0347-4","article-title":"Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320)","volume":"39","author":"Liebowitz","year":"2019","journal-title":"J Perinatol"},{"issue":"(2)","key":"2023112808583333000_i2331-348X-28-7-618-b20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1472-8206.2004.00314.x","article-title":"Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus","volume":"19","author":"Fanos","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"2023112808583333000_i2331-348X-28-7-618-b21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpeds.2018.03.067","article-title":"Association between furosemide exposure and patent ductus arteriosus in hospitalized infants of very low birth weight","volume":"199","author":"Thompson","year":"2018","journal-title":"J Pediatr"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/7\/618\/3293023\/i2331-348x-28-7-618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/7\/618\/3293023\/i2331-348x-28-7-618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:37:40Z","timestamp":1738780660000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/7\/article-p618.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11,23]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.7.618","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}